Conference Coverage

High-frequency spinal cord stimulation eases painful diabetic neuropathy


 

FROM ADA 2020

For patients with painful diabetic neuropathy that doesn’t resolve with standard treatment, use of a 10-kHz spinal cord stimulation device may relieve pain and improve sensation, initial results of a large randomized controlled trial suggest.

Some 79% of patients had substantial pain relief 3 months after starting treatment, compared with 5% of patients managed with conventional medical treatment, according to results of SENZA-PDN, which investigators say is the largest-ever randomized, controlled trial of spinal cord stimulation for managing painful diabetic neuropathy.

Although this was not a comparative trial, investigator Erika Petersen, MD, said in an interview that results seen with the 10-kHz spinal cord stimulator (Nevro Corp.) exceed what has been seen in previous studies of spinal cord stimulation devices operating at lower frequencies, where response rates have been in the 40%-55% range.

New option for front line providers?

“My overall takeaway here is that these initial 3-month results are very promising,” said Dr. Petersen, who is Director of Functional & Restorative Neurosurgery and Neuromodulation at the University of Arkansas for Medical Sciences in Little Rock.

Patient-perceived numbness and sensory assessments by investigators also improved following implantation of the spinal cord stimulator, according to Dr. Peterson, who added that measurements of sleep and activity also seemed to improve in these patients with painful diabetic neuropathy.

“Spinal cord stimulation has been established for chronic back and leg pain, but being able to innovate in this population with diabetic neuropathy is really something that we anticipate will improve quality of life and functional benefit for a large number of patients who currently have been stuck with the options that are currently available,” Dr. Petersen said in an interview.

Dr. Natalie Strand, of the Mayo Clinic, Scottsdale, Ariz. Courtesy Mayo Clinic

Dr. Natalie Strand

Natalie H. Strand, MD, assistant professor of pain medicine at Mayo Clinic, Scottsdale, Ariz., said that while the findings of this randomized study may require corroboration, they do suggest that this neuromodulation device may provide another option for front line diabetes providers when patients have persistent pain despite appropriately medication management.

“These patients are probably under-referred to interventional pain specialists,” said Dr. Strand in an interview. “The primary care physicians and endocrinologists may not think of neuromodulation as an appropriate treatment, and they may not know that it can be so effective.”

“Anything that we can add as physicians to help decrease the burden of diabetes is going to be very impactful,” Dr. Strand added. “While this is focused on pain, what we’re really trying to treat is the entire patient – improve their quality of life and make diabetes more manageable.”

Pages

Recommended Reading

FDA recalls extended-release metformin due to NDMA impurities
Clinician Reviews
10% with diabetes hospitalized for COVID-19 die within a week
Clinician Reviews
High out-of-pocket costs for type 1 diabetes patients: It’s not just insulin
Clinician Reviews
How old is too old for statins?
Clinician Reviews
Virtual ADA Scientific Sessions to offer full program
Clinician Reviews
Long-acting insulin analogue approved for type 1 and type 2 diabetes
Clinician Reviews
Half of type 1 diabetes patients with COVID-19 manage at home
Clinician Reviews
EMPA-REG OUTCOME: Empagliflozin cut insulin need in type 2 diabetes
Clinician Reviews
Starting new diabetes drugs less likely for racial minorities, Medicare Advantage beneficiaries
Clinician Reviews
Half of young adults with diabetes have diastolic dysfunction
Clinician Reviews